Tapentadol
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Tapentadol: From Moderate-to-Severe Pain to Migraine Disorder
One-Sentence Summary
Tapentadol is a centrally-acting opioid analgesic with a mu-opioid agonist and noradrenaline reuptake inhibition (NRI) component, used to treat moderate-to-severe pain. The TxGNN model predicts a possible effect in Migraine Disorder, but this direction is currently supported only by indirect literature (0 clinical trials, 2 general migraine-treatment reviews that do not evaluate tapentadol directly) and is contradicted by major headache-medicine guidance advising against opioid use in migraine.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Moderate-to-severe pain (opioid analgesic) — not explicitly recorded as a discrete field in the Evidence Pack; detailed original indication/MOA data are flagged as gaps (DG002) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.67% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for tapentadol is not available in this Evidence Pack (data gap DG002). Based on the information that is available, tapentadol acts as a mu-opioid receptor agonist combined with a noradrenaline reuptake inhibition (NRI) component. This dual mechanism is used clinically to manage moderate-to-severe pain, and the NRI element is pharmacologically related to descending pain-modulation pathways — a system also implicated in migraine pathophysiology (similar to how SNRIs are sometimes used off-label in migraine prevention).
On this basis, the TxGNN model has identified a theoretical mechanistic overlap between tapentadol’s pain-modulating pathway and migraine, which likely explains the high prediction score (99.67%).
However, this mechanistic plausibility is substantially offset by a significant negative signal already captured in the Evidence Pack: major headache-medicine guidelines (AHS/AAN) explicitly recommend against using opioid analgesics, including tapentadol, in migraine treatment. This is due to the well-established risk of medication-overuse headache (MOH) and the absence of evidence that opioids outperform existing migraine-specific therapies (triptans, NSAIDs, CGRP-targeted agents). This guideline-level caution is an important counterweight to the model’s high score and is the primary reason evidence strength remains low despite the strong prediction signal.
Clinical Trial Evidence
Currently no related clinical trials registered for tapentadol in migraine disorder.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27096578 | 2016 | Review (Cochrane) | Cochrane Database of Systematic Reviews | Reviews dipyrone (metamizole), not tapentadol, for postoperative/migraine pain; included for general analgesic-in-migraine context only |
| 27096438 | 2016 | Review (Cochrane) | Cochrane Database of Systematic Reviews | Reviews sumatriptan plus naproxen for acute migraine; establishes triptan/NSAID combinations as effective standard-of-care, not tapentadol |
Note: Neither publication evaluates tapentadol directly. They are included because they were the top-ranked literature matches in the Evidence Pack, and are presented here for transparency; they should be regarded as background context rather than direct supporting evidence.
UK Market Information
Tapentadol currently has no UK marketing authorisation on record in this Evidence Pack (0 licenses, market status: Not marketed). No product-specific authorisation table can be produced at this time.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Key warnings, contraindications, and drug–drug interaction data for tapentadol were not available in this Evidence Pack (flagged as a Blocking data gap, DG001). This gap must be resolved before any formal safety pre-assessment (S1) can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale:
- No clinical trials or drug-specific literature support the use of tapentadol in migraine; the evidence base is model-prediction-only (L5).
- The mechanistic rationale is directly contradicted by established headache-medicine guidance (AHS/AAN) against opioid use in migraine due to medication-overuse headache risk.
- Tapentadol has no UK marketing authorisation, and a Blocking safety data gap (product warnings/contraindications) prevents entry into formal safety evaluation.
To proceed, the following is needed:
- Product labelling / SmPC data (warnings and contraindications) to resolve the Blocking gap (DG001)
- Detailed mechanism-of-action documentation from DrugBank or equivalent source (DG002)
- Direct clinical or pharmacoepidemiological evidence evaluating tapentadol specifically in migraine populations
- Drug–drug interaction data, currently returned as “not found”
Additional note: Two lower-ranked predictions for tapentadol (migraine with brainstem aura; migraine susceptibility) were also generated by TxGNN but carry even weaker evidentiary support — one has zero associated literature or trials, and the other is linked to a genetic-susceptibility phenotype rather than an active disease state suitable for pharmacological intervention. Neither changes the overall Hold recommendation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.